AUTHORS
Suruchi Salgar, BS, Beatriz Bolivar2, Danitza Nebor, PhD3, Michelle Nguyen4, Brayden Barney5, Alexandra Brown-Suedel6, Dylan Pfannenstiel7, Chunsheng R. Chen, PhD8, Fuad R. Abdulla, DVM9, Lea Chamoun10, Iryna Khasabova, PhD11, Donald Simone, PhD12, John Hicks13, John D. Belcher I, PhD14, Gregory M. Vercellotti I, MD15, Jonathan Michael Flanagan, Assistant Professor16, Lisa Bouchier-Hayes, PhD17
AFFILIATIONS
1 Baylor College of Medicine, Houston, United States
2 Baylor College of Medicine, Houston, United States
3 Baylor College of Medicine, Houston, United States
4 Baylor College of Medicine, Houston, United States
5 Baylor College of Medicine, Houston, United States
6 Baylor College of Medicine, Houston, United States
7 Baylor College of Medicine, Houston, United States
8 University of Minnesota, Minneapolis, United States
9 University of Minnesota, Minneapolis, United States
10 University of Minnesota, Minneapolis, United States
11 University of Minnesota, Minneapolis, United States
12 University of Minnesota, Minneapolis, United States
13 Texas Children's Hospital, Houston, United States
14 University of Minnesota, Minneapolis, United States
15 University of Minnesota, Minneapolis, United States
16 Baylor College of Medicine, Houston, United States
17 Baylor College of Medicine, Houston, United States
ABSTRACT
Introduction: Heme is a key inducer of inflammation, vaso-occlusion, and organ damage in sickle cell disease (SCD). Heme activates the inflammatory caspase proteins (caspase-1, -4, and -5) to induce IL-1β release and cell death. Of the inflammatory caspases, only caspase-4 is required for both heme-induced IL-1β release and cell death. We investigated how heme activates caspase-4, and its murine homolog caspase-11, and their impact on vaso-occlusion and organ damage in SCD.
Results: To determine the ordering of this pathway, we used a fluorescence-based caspase-1 reporter to measure caspase-1 activation in primary human macrophages. Knockdown of caspase-4 prevented heme-induced caspase-1 activation (63 % vs 18 %, p<0.0001). We also measured caspase-1 cleavage as a marker of activation in the macrophage-like THP-1 cell line with or without caspase-4. Loss of caspase-4, but not loss of caspase-5, prevented heme-induced caspase-1 cleavage in these cells, indicating that caspase-4 is an apical enzyme in this pathway.
Because other inflammatory activators of caspase-4 directly bind it to induce activation, we investigated if heme binds caspase-4. We incubated heme-conjugated agarose beads with cell lysates or recombinant caspase-4. Heme pulled down caspase-4 endogenously expressed in THP-1 cells, caspase-11 in murine macrophage RAW264.7 cells, caspase-4 transiently expressed in HEK293T cells, and purified full-length caspase-4 protein (n=3). Using molecular docking, we identified candidate heme-binding residues in the catalytic domains of caspase-4, mutation of which significantly decreased pulldown of caspase-4 by heme-agarose. Thus, heme directly binds a novel binding site in the catalytic domains of caspase-4.
To determine if heme can induce caspase-4 oligomerization, the first step in its activation, we used native PAGE and SEC-MALS (size-exclusion chromatography with multi-angle light scattering) to assess purified catalytically inactive caspase-4 exposed to heme. Heme produced caspase-4 oligomers up to 1000 kDa in size, consistent with a high molecular weight active caspase complex. Furthermore, catalytically active purified caspase-4 exposed to heme underwent auto-cleavage, the second step in caspase activtation. These results indicate that heme binds to caspase-4 to induce its oligomerization and activation.
To determine how heme-induced caspase-4 activation impacts SCD, we deleted caspase-11 in the Townes SCD mouse model and measured two phenotypes that characterize SCD: chronic hyperalgesia and organ damage. Untreated HbSS Casp11-/- mice tolerated a greater degree of applied force before paw withdrawal (0.37 g vs 0.78 g, p=0.011), indicating decreased hyperalgesia levels. In untreated HbSS mice, caspase-11 loss did not impact markers of anemia severity (plasma heme, hemoglobin levels) or levels of many circulating immune cell types (total white blood cells, neutrophils, monocytes, platelets) at 8 and 22 weeks of age. Only circulating lymphocytes were slightly decreased in older HbSS Casp11-/- mice (33.5 vs 26.3 K/µl, p = 0.017). Despite similar heme and leukocyte levels, 22-week-old HbSS Casp11-/- mice had less liver ischemia (2.5% vs 0.4% area, p = 0.001) and lower markers of tissue and liver damage including circulating LDH (1046 vs 494 U/L, p = 0.041), ALT (466.6 vs 183.6 U/L, p = 0.039), and AST (314 vs 148 U/L, p = 0.028). 22-week-old HbSS Casp11-/- mice also had lower levels of IL-6, a cytokine associated with chronic inflammation and tissue damage in SCD. Thus, loss of caspase-11 protects from chronic liver damage and hyperalgesia in murine SCD.
To determine the contribution of caspase-4 to heme-induced vaso-occlusion, the hallmark complication of SCD, we infused SCD mice with heme. Liver expression of pro-inflammatory and pro-adhesion proteins IL-1β, IL-18, NF-κB phospho-p65, VCAM, and E-selectin were significantly lower in HbSS Casp11-/- mice. 1 h following infusion, loss of caspase-11 resulted in significantly reduced vascular stasis (29.8 % vs 8.5 %, p < 0.0001). Thus, caspase-11 contributes to heme-mediated vaso-occlusion.
Conclusions: Our data show that heme directly binds to caspase-4/11 to induce caspase-4 and -1 activation, providing a mechanism for how caspase-4/11 contributes to inflammation, vaso-occlusion, pain, and chronic liver damage in SCD mice. Thus, caspase-4 is a promising therapeutic target to prevent severe inflammatory complications of SCD.
DISCLOSURES
Suruchi Salgar, BS: No relevant conflicts of interest to declare.